The findings of the present study developed a gene therapy technology for removal of the aberrant PMP22 gene copy that causes CMT1A by genome editing using iPSC-derived Schwann cells from CMT1A patients. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.